{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-046841","form_type":"8-K","ticker":"ONCO","cik":"0001782107","company_name":"Onconetix, Inc.","filed_at":"2023-06-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.538409+00:00","generated_at":"2026-06-14T06:43:17.444708+00:00","sec_items":["1.01","5.02","5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Blue Water Biotech adopts 401(k) plan, reduces stockholder quorum, and approves equity plan increase at annual meeting","bullets":["Adopted 401(k) Safe Harbor Non-Elective Plan effective July 1, 2023; company contributes 3% of gross pay, immediate vesting.","Bylaws amended to reduce stockholder quorum requirement from majority to one-third of voting power, effective immediately.","Annual meeting results: James Sapirstein elected Class II director for three-year term; 6.2M votes for, 657K withheld.","Amendment to 2022 Equity Incentive Plan approved, increasing authorized shares by 550,000 to 3,150,000 total.","Ratified Mayer Hoffman McCann P.C. as independent auditor for fiscal year ending December 31, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-046841","json":"https://secwatch.observer/filing/0001213900-23-046841.json","markdown":"https://secwatch.observer/filing/0001213900-23-046841.md","text":"https://secwatch.observer/filing/0001213900-23-046841.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023046841/0001213900-23-046841-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023046841/ea179858-8k_bluewater.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T06:43:17.444708+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4910dcc6fe5553db6ba80391db40f68429e048b5","claim":"Onconetix, Inc.: Amended bylaws to reduce stockholder meeting quorum requirement from a majority to one-third of voting power (effective 2023-05-31).","evidence_excerpt":"On May 31, 2023, the Board amended the Company’s bylaws to reduce the quorum requirement at meetings of the Company’s stockholders from a majority of the voting power of the outstanding shares of stock of the Company entitled to vote, to one-third of the voting power of the outstanding shares of stock of the Company entitled to vote, effective immediately.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023046841/0001213900-23-046841-index.htm","confidence":0.95,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-05-31"}],"fact_type":"governance_change"},{"claim_id":"5232a86152210ded44c861cf37778bd1fd5a89c1","claim":"Onconetix, Inc. shareholders approved Ratification of the appointment of Mayer Hoffman McCann P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-05-31 meeting.","evidence_excerpt":"Proposal No. 3 – Ratification of the appointment of independent registered public accounting firm Appointment by the Company’s audit committee of Mayer Hoffman McCann P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified. The voting results were as follows: Shares Voted For Shares Voted Against Shares Abstaining Broker Non-Vote 9,717,035 248,537 5,889 -","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023046841/0001213900-23-046841-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-31"}],"fact_type":"shareholder_vote"},{"claim_id":"ccfcfd48a876e71eb24e841935f1ac9a490c909e","claim":"Onconetix, Inc. shareholders approved Election of Mr. James Sapirstein as a Class II director to serve for a three-year term that expires at the 2026 annual meeting of stockholders or until his successor is elected and qualified at the 2023-05-31 meeting.","evidence_excerpt":"Proposal No. 1 – Election of Directors Mr. James Sapirstein was elected as a Class II director to serve for a three-year term that expires at the 2026 annual meeting of stockholders or until his successor is elected and qualified. The voting results were as follows: Nominee Shares Voted For Shares Withheld Broker Non-Vote James Sapirstein 6,207,510 656,947 3,107,004","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023046841/0001213900-23-046841-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-31"}],"fact_type":"shareholder_vote"},{"claim_id":"f071aeb60c2cba7ca8a4cea15bc4d3da37dce21c","claim":"Onconetix, Inc. shareholders approved Amendment to the Amended and Restated 2022 Equity Incentive Plan to increase the aggregate number of shares of Common Stock which may be issued under the plan by 550,000 shares from 2,600,000 to 3,150,000 shares at the 2023-05-31 meeting.","evidence_excerpt":"Proposal No. 2 – Amendment to 2022 Equity Incentive Plan The amendment to the 2022 Plan to (i) increase the aggregate number of shares of Common Stock which may be issued under the plan by 550,000 shares from 2,600,000 to 3,150,000 shares was approved. The voting results were as follows: Shares Voted For Shares Voted Against Shares Abstaining Broker Non-Vote 6,191,117 659,202 14,138 3,107,004","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023046841/0001213900-23-046841-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-31"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}